Prior Use of Infliximab As a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn's Disease: Analyses From the Precise 3 7-Year Study

被引：0
|
作者：
Rubin, David T.
Coarse, Jason
Kosutic, Gordana
Spearman, Marshall
Ambarkhane, Sumeet
Jojic, Njegica
机构：
来源：
GASTROENTEROLOGY | 2014年 / 146卷 / 05期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
Sa1274
引用
收藏
页码：S249 / S249
页数：1
相关论文
共 50 条
  • [1] Long-term safety and efficacy of certolizumab pegol in the treatment of Crohn's disease: 7-year results from the PRECiSE 3 study
    Sandborn, W. J.
    Lee, S. D.
    Randall, C.
    Gutierrez, A.
    Schwartz, D. A.
    Ambarkhane, S.
    Kayhan, C.
    Pierre-Louis, B.
    Schreiber, S.
    Lichtenstein, G. R.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 40 (08) : 903 - 916
  • [2] Long-Term Outcomes of Certolizumab Pegol for Crohn's Disease: 7 Year Results From the PRECiSE 3 Study
    Sandborn, William
    Lee, Scott D.
    Randall, Charles W.
    Gutierrez, Alexandra
    Schwartz, David A.
    Ambarkhane, Sumeet
    Kayhan, Cem
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Schreiber, Stefan
    Lichtenstein, Gary R.
    [J]. GASTROENTEROLOGY, 2014, 146 (05) : S588 - S589
  • [3] Disease Activity as a Predictor of Long-Term Outcomes of Treatment With Certolizumab Pegol for Active Crohn's Disease: An Analysis of the PRECiSE 3 Study
    Choi, Jennifer
    Abraham, Bincy
    Wolf, Douglas
    Colombel, Jean-Frederic
    Kosutic, Gordana
    Spearman, Marshall
    Coarse, Jason
    Sandborn, William
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S509 - S510
  • [4] Serum Albumin as a Predictor of Long-Term Response and Remission With Certolizumab Pegol for Crohn's Disease: Results From 7-Year Data From the PRECiSE 3 Study
    Sandborn, William
    Macrae, Finlay
    Lawrance, Ian
    Sen, David
    Abbas, Sarah
    Douglas, Kevin
    Lichtenstein, Gary
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S512 - S512
  • [5] Clinical and demographic characteristics predictive of treatment outcomes for certolizumab pegol in moderate to severe Crohn's disease: analyses from the 7-year PRECiSE 3 study
    Sandborn, W. J.
    Melmed, G. Y.
    McGovern, D. P. B.
    Loftus, E. V., Jr.
    Choi, J. M.
    Cho, J. H.
    Abraham, B.
    Gutierrez, A.
    Lichtenstein, G.
    Lee, S. D.
    Randall, C. W.
    Schwartz, D. A.
    Regueiro, M.
    Siegel, C. A.
    Spearman, M.
    Kosutic, G.
    Pierre-Louis, B.
    Coarse, J.
    Schreiber, S.
    [J]. ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2015, 42 (03) : 330 - 342
  • [6] Long-term tolerability of subcutaneous certolizumab pegol in active Crohn's disease: Results from precise 3 and 4
    Colombel, Jean-frederic
    Schreiber, Stefan
    Hanauer, Stephen B.
    Rutgeerts, Paul
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A503 - A503
  • [7] Reinduction with Certolizumab Pegol in Patients with Crohn's Disease Experiencing Disease Exacerbation: 7-Year Data from the PRECiSE 4 Study
    Lee, Scott D.
    Rubin, David T.
    Sandborn, William J.
    Randall, Charles
    Younes, Ziad
    Schreiber, Stefan
    Schwartz, David A.
    Burakoff, Robert
    Binion, David
    Dassopoulos, Themos
    Arsenescu, Razvan
    Gutierrez, Alexandra
    Scherl, Ellen
    Kayhan, Cem
    Hasan, Iram
    Kosutic, Gordana
    Spearman, Marshall
    Sen, David
    Coarse, Jason
    Hanauer, Stephen
    [J]. INFLAMMATORY BOWEL DISEASES, 2016, 22 (08) : 1870 - 1880
  • [8] Long-term treatment with certolizumab pegol for up to 18 months in patients with active Crohn's disease: Precise 3 efficacy results
    Schreiber, Stefan
    Hanauer, Stephen B.
    Feagan, Brian G.
    Bloomfield, Ralph
    Rutgeerts, Paul
    Sandborn, William J.
    [J]. GASTROENTEROLOGY, 2007, 132 (04) : A504 - A504
  • [9] Predictors of Maintenance of Long-term Remission in Crohn's Disease Patients Treated With Certolizumab Pegol: Multivariate and Univariate Analyses From the PRECiSE 3 Study
    Sandborn, William
    Schreiber, Stefan
    Siegel, Corey
    Melmed, Gil
    McGovern, Dermot
    Pierre-Louis, Bosny
    Kosutic, Gordana
    Spearman, Marshall
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S514 - S514
  • [10] Long-term remission with certolizumab pegol in Crohn's disease over 3.5 years: results from the PRECiSE 3 study
    Lichtenstein, G.
    Thomsen, O.
    Schreiber, S.
    Lawrance, I
    Hanauer, S.
    Bloomfield, R.
    Sandborn, W.
    [J]. INFLAMMATORY BOWEL DISEASES, 2009, 15 (12) : S12 - S13
12345